{"id":740973,"date":"2025-04-26T08:12:02","date_gmt":"2025-04-26T08:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=740973"},"modified":"2025-04-26T08:12:02","modified_gmt":"2025-04-26T08:12:02","slug":"bullous-keratopathy-market-poised-for-robust-growth-at-an-115-cagr-over-the-coming-decade-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bullous-keratopathy-market-poised-for-robust-growth-at-an-115-cagr-over-the-coming-decade-delveinsight_740973.html","title":{"rendered":"Bullous Keratopathy Market Poised for Robust Growth at an 11.5% CAGR Over the Coming Decade | DelveInsight"},"content":{"rendered":"
The bullous keratopathy treatment market is projected to experience substantial growth over the coming decade, driven by an aging population, increasing prevalence of cataract surgeries, glaucoma procedures, and novel pharmaceutical interventions by key bullous keratopathy players such as Aurion Biotechnologies, Emmecell, Trefoil Therapeutics, and Cellusion, among others.<\/div>\n

DelveInsight’s “Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast – 2034<\/a><\/strong>” report delivers an in-depth understanding of bullous keratopathy, historical and forecasted epidemiology, as well as the bullous keratopathy market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The report provides detailed insights into current treatment practices, bullous keratopathy emerging therapies, and market dynamics from 2020 to 2034, offering a comprehensive assessment of this evolving therapeutic landscape. This analysis serves as a crucial resource for stakeholders seeking to understand market potential and identify strategic opportunities in the bullous keratopathy treatment market.<\/p>\n

According to DelveInsight’s market assessment, the bullous keratopathy market size in the 7MM was valued at approximately USD 14 million in 2023<\/strong> and is projected to grow at a robust CAGR of 11.5%<\/strong> during the forecast period (2024-2034). The US currently dominates the market, followed by the EU4 and UK regions, with Japan representing a significant growth opportunity due to its aging population and high prevalence of cataract surgeries. This market expansion reflects increasing disease awareness, improved diagnostic capabilities, and the anticipated launch of novel therapeutic interventions addressing the substantial unmet needs in bullous keratopathy management.<\/p>\n

Download the bullous keratopathy market report to understand which factors are driving the bullous keratopathy therapeutic market @ Bullous Keratopathy Market Trends<\/a>.<\/strong><\/p>\n

The report provides comprehensive epidemiological insights, revealing that approximately 200K diagnosed prevalent cases of bullous keratopathy were recorded across the 7MM in 2023, with the US accounting for the largest share at 41% of total cases<\/strong>. According to DelveInsight’s analysis, the prevalence is expected to increase steadily through 2034, primarily due to demographic shifts toward an aging population and the rising volume of cataract surgeries, intraocular lens implantations, and other invasive ocular procedures that can damage corneal endothelial cells.<\/p>\n

The current bullous keratopathy treatment landscape primarily relies on corneal transplantation techniques, particularly endothelial keratoplasty (EK) procedures, including Descemet’s stripping automated endothelial keratoplasty (DSAEK) and Descemet’s membrane endothelial keratoplasty (DMEK). While these surgical interventions can effectively restore vision, they face significant challenges, including limited donor cornea availability, risk of graft rejection, surgical complications, and substantial healthcare costs. Symptomatic management with hypertonic saline solutions, bandage contact lenses, and lubricating eye drops provides temporary relief but fails to address the underlying endothelial cell dysfunction, highlighting the critical need for innovative therapeutic approaches.<\/p>\n

Discover emerging trends in the bullous keratopathy treatment landscape @ Bullous Keratopathy Therapies Market<\/a>.<\/strong><\/p>\n

The bullous keratopathy pipeline has shown promising advancement in recent years, with several innovative therapies in clinical development. Aurion Biotechnologies (NYSE: AURN)<\/strong> has emerged as a pioneer with VYZNOVA<\/strong>, a cell therapy product launched in Japan in September 2024, which represents a significant step forward in treating bullous keratopathy. Emmecell<\/strong> is progressing with EO2002<\/strong>, completing the final dose administration for the last patient in its US Phase I trial in April 2024, with a Phase III pivotal study scheduled for the first quarter of 2025. Additional promising candidates include TTHX1114 (NM141) by Trefoil Therapeutics<\/strong> and CLS001 by Cellusion<\/strong>, which aim to either regenerate corneal endothelial cells or provide novel mechanisms to address corneal edema and bullae formation.<\/p>\n

Unlock which bullous keratopathy emerging therapy is expected to capture the largest market share in 7MM by 2034. Visit the Bullous Keratopathy Market Insights<\/a>.<\/strong><\/p>\n

Recent developments in the bullous keratopathy clinical trials landscape have generated significant optimism. In January 2025, preliminary results from a Phase II study of a novel Rho-kinase inhibitor<\/strong> demonstrated substantial improvement in corneal clarity and thickness in patients with moderate bullous keratopathy, suggesting potential as a non-surgical intervention. Additionally, early data from a corneal endothelial cell expansion technology being developed through a collaboration between academic research institutions and industry partners has shown promising results in ex vivo studies, potentially offering a solution to donor tissue shortages for transplantation procedures.<\/p>\n

Despite these advancements, significant challenges<\/a> remain in the bullous keratopathy treatment market. Limited disease awareness among primary care physicians and general ophthalmologists can lead to delayed diagnosis and intervention. The complex nature of corneal endothelial cell biology presents hurdles for developing targeted pharmacological approaches, while high treatment costs and limited reimbursement pathways create access barriers, particularly for innovative cell therapies. DelveInsight’s analysis emphasizes that addressing these challenges will require coordinated efforts among healthcare stakeholders, including enhanced physician education, streamlined regulatory pathways for cell-based therapies, and the adoption of value-based reimbursement models.<\/p>\n

Looking ahead, the bullous keratopathy market is poised for transformation through the advancement of cellular therapies, targeted pharmacological agents, and tissue engineering approaches. The integration of artificial intelligence in diagnosing and monitoring disease progression is expected to enhance treatment planning and outcomes assessment. Additionally, combination therapies targeting multiple aspects of corneal endothelial dysfunction may provide more comprehensive and durable benefits than current single-modality approaches. With increasing investment in research and development, along with a greater focus on this previously underserved condition, patients with bullous keratopathy can expect expanded treatment options and an improved quality of life in the coming decade.<\/p>\n

Table of Contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Report Introduction<\/p>\n

3. Bullous Keratopathy Market Overview at a Glance<\/p>\n

4. Methodology of Bullous Keratopathy Epidemiology and Market<\/p>\n

5. Executive Summary of Bullous Keratopathy<\/p>\n

6. Key Events<\/p>\n

7. Bullous Keratopathy Background and Overview<\/p>\n

8. Bullous Keratopathy Patient Journey<\/p>\n

9. Bullous Keratopathy Epidemiology and Patient Population<\/p>\n

10. Bullous Keratopathy Marketed Drugs<\/p>\n

11. Bullous Keratopathy Emerging Drugs<\/p>\n

12. Bullous keratopathy: Market Analysis<\/p>\n

13. Key Opinion Leaders’ Views<\/p>\n

14. SWOT<\/p>\n

15. Bullous Keratopathy Unmet Needs<\/p>\n

16. Market Access and Reimbursement<\/p>\n

17. Appendix<\/p>\n

18. DelveInsight Capabilities<\/p>\n

19. Disclaimer<\/p>\n

20. About DelveInsight<\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Arpit Anand
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

The bullous keratopathy treatment market is projected to experience substantial growth over the coming decade, driven by an aging population, increasing prevalence of cataract surgeries, glaucoma procedures, and novel pharmaceutical interventions by key bullous keratopathy players such as Aurion Biotechnologies, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-740973","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/740973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=740973"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/740973\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=740973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=740973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=740973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}